Allergan rejects Valeant Pharma’s ‘cut and slash’ takeover

[Reuters – UK Focus] – * Allergan (NYSE: AGN – news) says offer undervalues company * Allergan expects EPS growth of 20-25 percent (Adds background, analyst comment) May 12 (Reuters) – U.S. drugmaker Allergan Inc on Monday rejected Valeant Pharmaceutical more

View todays social media effects on VRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Valeant is hiring next, click here to view